REFERENCES
- Bricker NS. Slatopolsky E, Reiss E, Avioli LV. Calcium, phosphorus and bone in renal disease and transplantation. Arch Intern Med 1969; 123: 543–553.
- Llach F, Massry SG. The mechanism of secondary hyperparathyroidism in moderate renal failure. J Clin Endocrinol Metab 1985; 61: 601–606.
- Parkinson IS, Ward MK, Kerr DNS. Dialysis encephalopathy bone disease and anaemia: the aluminium intoxication syndrome during regular haemodialysis. J Clin Pathol 1981; 34: 1285–1294.
- Clarkson EM, McDonald SJ. Wardener HE de. The effect of high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci 1966; 30: 425–438.
- Sheikh MS, Ramirez A. Emmett M. Santa Ana C, Schiller LR, Fordtran JS. Role of vitamin D-dependent and vitamin D independent mechanisms in absorption of food and calcium. J Clin Invest 1988; 81: 126–132.
- Anelli A, Brancaccio D. Damasso R, Padovese P. Gallieni M, Garella S. Substitution of calcium carbonate for aluminium hydroxide in patients on haemodialysis. Nephron 1989; 52: 125–132.
- Ittel TH. Schafer C, Schmitt H. Gladziwa U. Sieberth HG. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric coated preparation and effect of additional aluminium hydroxide on hyperaluminacmia. Klin Wochenschr 1991; 69: 59–67.
- Davenport A, Goel S, Mackenzie JC. Audit of the use of calcium carbonate as a phosphate binder in 100 patients treated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1992 (in press).
- Kanis JA. Disorders of calcium metabolism. In Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine. 2nd Ed, Oxford: University Press 1987: 10.51–10.52.
- Bongiorno P, Caligaris F, Montalcini G, Biamino E, Imariso P, Dagna L. Arnaud A. Utilizzo del calcio carbonate (CaCO3) come chelante intestinale del fosforo. Min Urol Nefrol 1990; 42: 55–57.
- Hercz G, Kraut JA, Andress DA, Howard N. Roberts C, Shinaberger JH, Sherrard DJ, Coburn JW. Use of calcium carbonate as a phosphate binder in dialysis patients. Min Electrolyte Metab 1986; 12: 314–319.
- Meric F, Yap P, Bia MJ. Aetiology of hypercalcaemia in haemodialysis patients on calcium carbonate therapy. Am J Kid Dis 1990; 16: 459–464.
- Faugere MC, Malluche HH. Stainable aluminium and not aluminium content reflects bone histology in dialyzed patients. Kid Int 1986; 30: 717–722.
- Sherrard DJ. Aluminium and renal osteodystrophy. Seminars in Nephrol 1986; 6: 5–11.
- Boyce BF, Elder HY, Elliot HL, Fogelman I. Fell GS, Junor BJ, Beastall G, Boyle IT. Hypercalcaemic osteodystrophy due to aluminium toxicity. Lancet 1982; ii: 1009–1012.
- Sawyer N, Newstead C, Drummond A, Newland A, Cunningham J. One shot high dose pamidronate disodium (APD): effective simple treatment for hypercalcaemia in haematological malignancy. Clin Lab Haemat 1989; 11: 179–184.
- Fraser WD, Logue FC, Gallacher SJ, O'Reilly DSt.J, Beastall GH, Ralston SH, Boyle IT. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy. Bone Miner 1991; 12: 113–121.
- Gallacher SJ, Ralston SH, Dryburgh FJ, Logue FC, Allam BF, Boyce BF, Boyle IT. Immobilisation related hypercalcaemia–a possible novel mechanism and response to pamidronate. Postgrad Med J 1990; 66: 918–922.
- Fleisch H. Biphosphonates: mechanisms of action and clinical applications. In Peck WA, ed. Bone and Mineral Research Annual 1. Amsterdam: Excerpta Medica, 1982: 319–357.
- Lowik CWGM, van der Pluijm G, van der Wee-Pals LJA, van Treslong-de Groot HB, Bijvoet OLM. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a biphosphonate. J Bone Miner Res 1988; 3: 185–192.
- Malluche HH, Faugere MC. Aluminium related bone disease. Blood Purif 1988; 6: 1–15.
- Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289–318.